Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Pengyu Geng"'
Autor:
Pengyu Geng, Fei Ye, Peng Dou, Chunxiu Hu, Jiarui He, Jinhui Zhao, Qi Li, Miao Bao, Xiangnan Li, Xinyu Liu, Guowang Xu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-14 (2024)
Abstract Background The mutations of oncogenic epidermal growth factor receptor (EGFR) is an important cause of lung adenocarcinoma (LUAD) malignance. It has been knowm that metabolic reprogramming is an important hallmark of malignant tumors, and pu
Externí odkaz:
https://doaj.org/article/45faf18145df4198aa60bc3011df6119
Autor:
Pengyu Geng, Jinhui Zhao, Qi Li, Xiaolin Wang, Wangshu Qin, Ting Wang, Xianzhe Shi, Xinyu Liu, Jia Chen, Hongdeng Qiu, Guowang Xu
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 17046 (2023)
Lung cancer is a malignant tumor with one of the highest morbidity and mortality rates in the world. Approximately 80–85% of lung cancer is diagnosed as non-small lung cancer (NSCLC), and its 5-year survival rate is only 21%. Cisplatin is a commonl
Externí odkaz:
https://doaj.org/article/c301135847644b139e6e813069fa00e3
Autor:
Yalei Yin, Mingju Sun, Xi Zhan, Changqing Wu, Pengyu Geng, Xiaoyan Sun, Yunsong Wu, Shuijun Zhang, Jianhua Qin, Zhengping Zhuang, Yang Liu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Abstract Background The bromodomain and extra-terminal domain (BET) inhibitor is a type of anti-tumor agent, currently being evaluated in phase I and II clinical trials for cancer therapy. It can decrease MYC expression levels and cause effective ant
Externí odkaz:
https://doaj.org/article/13ff380173ff45968f07c4a4582fd20d
Publikováno v:
Environmental Science & Technology. 57:4027-4038
Autor:
Yang Liu, Guowang Xu, Zhengping Zhuang, Enyou Li, Peng Gao, Jane Yu, Lei Guo, Chunxiu Hu, Peiyuan Yin, Jiao Wang, Changsong Wang, Mingju Sun, Yang Wang, Chengnan Fang, Pengyu Geng, Jun Zeng, Ling Tang
Table S1. Clinical information of enrolled subjects for discovery; Table S2. Clinical information of enrolled hepatic carcinoma subjects for validation; TableS3. Differential metabolites obtained from tissue specimens in metabolomics discovery; Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b44bf5aeb0a59a1ec441db9819dfcf41
https://doi.org/10.1158/1078-0432.22465692
https://doi.org/10.1158/1078-0432.22465692
Autor:
Yang Liu, Guowang Xu, Zhengping Zhuang, Enyou Li, Peng Gao, Jane Yu, Lei Guo, Chunxiu Hu, Peiyuan Yin, Jiao Wang, Changsong Wang, Mingju Sun, Yang Wang, Chengnan Fang, Pengyu Geng, Jun Zeng, Ling Tang
Purpose: Metabolic reprogramming is frequently identified in hepatocellular carcinoma (HCC), which is the most common type of liver malignancy. The reprogrammed cellular metabolisms promote tumor cell survival, proliferation, angiogenesis, and metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8205ede540ba1857871430ee77a5ea69
https://doi.org/10.1158/1078-0432.c.6526119.v1
https://doi.org/10.1158/1078-0432.c.6526119.v1
Publikováno v:
Amino acids. 53(12)
Cancer cells often change their metabolism to support uncontrolled proliferation. Proline is the only proteogenic secondary amino acid that is abundant in the body. Recent studies have shown that proline metabolism plays an important role in metaboli
Autor:
Mingju Sun, Pengyu Geng, Shuijun Zhang, Yalei Yin, Zhengping Zhuang, Changqing Wu, Yang Liu, Xi Zhan, Jianhua Qin, Yunsong Wu, Xiaoyan Sun
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Background The bromodomain and extra-terminal domain (BET) inhibitor is a type of anti-tumor agent, currently being evaluated in phase I and II clinical trials for cancer therapy. It can decrease MYC expression levels and cause effective anti-tumor e
Autor:
Musong Ma, Jun Lu, Meichen Dong, Zhongwei Li, Dongmei Fan, Adhanom Mihretab, Hongyuan Li, Baiqu Huang, Ruosi Yao, Pingfu Hou, Pengyu Geng, Yu Zhang, Dong-Xu Liu, Guannan Wang, Yuxin Li
Publikováno v:
Cell Death & Differentiation. 24:59-71
EZH2 (the Enhancer of Zeste Homolog 2), as a key epigenetic regulator and EMT inducer, participates in a variety of cancer metastasis. EZH2 stability is regulated by several types of post-translational modifications (PTMs).The long non-coding RNAs (l